Measuring the CD180 protein on blood cells in acute myeloid leukemia
Studies CD180 levels on leukemia cells and healthy blood stem cells.
Plain-language title generated from the registry record
Registry title: Characterization of CD180 Protein Expression in Myeloid Hematological Malignancies by Flow Cytometry
Key facts
- Where
- Strasbourg, FranceSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and adults with confirmed or suspected acute myeloid leukemia who had a bone marrow test. It uses leftover samples from routine care.
- Age
- 1 year and older (children 1 to 17 years and adults 18 years or older)
- Sex
- All sexes can join.
- Disease stage
- Confirmed or suspected acute myeloid leukemia, tested at diagnosis or at relapse. Patients whose stem cells are checked on a blood or bone marrow sample can also join.
Main reasons for not taking part
- Patients or legal representatives who objected to reuse of personal data for research
- Samples more than 72 hours old
- Clotted samples
- Samples with too little volume (less than 10 microliters)
Read by machine on 12 November 2026.
Where in France
- Laboratoire d'Hématologie Biologique - CHU de Strasbourg - FranceStrasbourg, FranceContact: Laurent Mauvieux, MD, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Hospital, Strasbourg, France
- Trial code
- NCT07895901
- Record updated
- 26 October 2026
- Original description
CD180 is a cell-surface protein recently identified through proteomic analysis as a potential target of interest in myeloid hematological malignancies. It may have diagnostic and monitoring potential, particularly in acute myeloid leukemia (AML).Read full original descriptionShow less
Characterization of CD180 Protein Expression in Myeloid Hematological Malignancies by Flow Cytometry
CD180 is a cell-surface protein recently identified through proteomic analysis as a potential target of interest in myeloid hematological malignancies. It may have diagnostic and monitoring potential, particularly in acute myeloid leukemia (AML).
This monocentric, non-interventional, retrospective observational study aims to characterize CD180 expression by flow cytometry in pathological hematopoietic cells, particularly in AML, and in normal hematopoietic stem and progenitor cells (CD34+ cells). The study will use residual blood and bone marrow samples collected during routine care and otherwise intended for disposal by incineration, together with relevant clinical and laboratory data.
Inclusion: Adult patients aged 18 years or older; Pediatric patients aged 1 to 17 years; Patients with confirmed or suspected acute myeloid leukemia who have undergone bone marrow aspiration as part of the diagnostic or relapse assessment; Patients whose stem cells are being assessed using a blood or bone marrow sample; Patients and/or their legal representatives, where applicable, informed by letter of the use of residual sample material for research purposes; No written objection documented in the medical record to the reuse of personal data for scientific research.
Exclusion: Patients and/or their legal representatives, where applicable, who have objected to the reuse of personal data for scientific research; Samples more than 72 hours old; Clotted samples; Samples with insufficient volume (less than 10 microliters).